Chief Science Officer
Dr. Carl Ascoli is currently serving as Chief Science Officer for Rockland Immunochemicals Inc. and has more than 30 years of academic and industrial experience. Dr. Ascoli’s responsibilities involve all divisions of the laboratory including production, research and development, quality control, quality assurance, and technical service. Dr. Ascoli works with a team of scientific team leaders who head each of these groups. Through collaborative efforts, Dr. Ascoli and these team leaders carry out strategic planning, problem-solving, creative thinking, and resource allocation.
Under his guidance, Rockland has developed thousands of primary antibodies against targets involved in cancer and other cell signaling pathways. Many of these antibodies were developed into immunoassays including assays for putative biomarkers for various diseases.
Dr. Ascoli has a Doctorate in Biochemistry from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ). He received his postdoctoral training in autoimmune diseases focusing on autoantibodies and autoantigens associated with primary biliary cirrhosis from the Wistar Institute in Philadelphia, Pennsylvania.
Facts About Me
- I have a Doctorate in Biochemistry from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)
- I received postdoctoral training in autoimmune diseases focusing on autoantibodies and autoantigens associated with primary biliary cirrhosis from the Wistar Institute in Philadelphia, Pennsylvania
- I have developed thousands of research antibodies – in one instance an antibody we developed was included in the payload of experiments on a space shuttle mission.
- I was first to discover PML nuclear bodies within the nucleus using autoimmune serum for visualization
- I was mayor of my town for six years
Top Skills
- Nucleic Acid Biochemistry
- Antibody Purification
- Immunoassay Development
- Post Translational Modifications
- Immunofluorescence Microscopy
Articles
-
2D-SDS PAGE Analysis Methods For Determining HCP Coverage Using Process Derived anti-HCP Polyclonal Antibodies
In this poster, we present the characterization of a process specific anti-Pichia pastoris HCP antibody using 2 different analysis platforms: Biorad’s PD Quest and Total Lab’s Spot Map. -
Localization of HDAC1 using high resolution microscopy
Poster discussing the localization of HDAC1 using high resolution microscopy. -
Highly Specific and Sensitive Nanoimmunoassay of PARP1: A Toolkit to Measure Cell Death
This poster explores our development of highly sensitive and specific antibodies against PARP1 fragments. -
Production and Characterization of High Coverage, Process Specific Pichia P. HCP Antibodies
Describing the process of developing high coverage, process-specific HCP antibodies for the determination of HCPs in the production of recombinant human protein.